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Abstract
Background: Patients with advanced or recurrent thymic epithelial tumors (TETs) often need several consecutive lines
of chemotherapy. The aim of this retrospective monocentric study was to test whether 18F-Fluorodeoxyglucose
positron emission tomography-computed tomography (18F-FDG PET-CT) is able to monitor standard chemotherapy
efficacy in those patients and whether metabolic response correlates with morphovolumetric response as assessed by
Response Evaluation Criteria in Solid Tumor (RECIST).
Methods: We evaluated 27 consecutive patients with advanced (16 patients) or recurrent (11 patients) TETs. All patients
underwent 18F-FDG PET-CT before and after at least 3 cycles of chemotherapy. Maximum standardized uptake value (SUVmax)
of all detected lesions was recorded and the most 18F-FDG avid lesion in each patient was selected for determination
of percentage change of SUVmax (ΔSUVmax) in pre- and post-treatment scans. Tumor response was assessed by contrast-
enhanced computed tomography (CE-CT) using RECIST criteria. Receiver operating characteristic (ROC) curve analysis was
performed to define the optimal threshold of ΔSUVmax discriminating responders from non-responders.
Results: Metabolic response expressed as ΔSUVmax was significantly correlated with morphovolumetric
response (Spearman’s rank correlation, r = 0.64, p = 0.001). ROC curve analysis showed that a ΔSUVmax value of -25%
could discriminate responders from non-responders with a sensitivity of 88% and a specificity of 80%. Conversely, basal
SUVmax values were not predictive of morphovolumetric tumor response.
Conclusions: Our findings indicate that metabolic response assessed by 18F-FDG PET-CT, through evaluation of
ΔSUVmax, may allow identification of responders and non-responders thus guiding adaptation of therapy in patients
with advanced or recurrent TETs.
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Background
Thymic epithelial tumors (TETs) are rare malignancies
arising in the anterior mediastinum showing a high
variable biological behaviour, from slow-growing benign
lesions to highly aggressive carcinomas [1, 2]. According
to the histological classification of the World Health
Organization (WHO), TETs are subdivided into type A,
AB, B1, B2, B3 and thymic carcinomas, characterized by
an increasing degree of malignancy [1]. Thymic epithelial
tumors are routinely staged according to Masaoka-Koga
staging system, that considers the integrity of the thymic
capsule (stage I), the micro or macroscopic invasion of
surrounding tissues and organs (stage II and III), the
presence of pleural or pericardial metastasis (stage IVA)
and the lymphogenous or haematogenous metastatic
spread (stage IVB) [3, 4]. Although both WHO classifica-
tion and Masaoka-Koga staging system contribute to risk
stratification of patients with TETs, therapeutic decisions
are essentially taken on the basis of disease stage [5, 6]
since WHO classification appeared to have a limited
clinical predictive value [7].
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The treatment strategy for thymic epithelial tumour
is primarily based on whether the tumor can be rad-
ically resected or not at diagnosis [8–10]. Although
surgery remains the treatment of choice, most of
these tumors are unresectable or in advanced stages
at diagnosis and require chemotherapy, eventually
followed by surgery if tumors become resectable after
the planned regimen. Furthermore, despite radical re-
section, recurrence is quite common in those patients
and, although recurrent lesions are managed with the
same approach used for newly diagnosed TETs, multi-
course therapy is often necessary [8–10]. Cisplatin-
based combination regimens are usually administered
to patients candidate for both neoadjuvant and pallia-
tive chemotherapy [11–14]. Several consecutive lines
of chemotherapy are also available for patients pre-
senting tumor progression.
In this clinical context imaging modalities are of
primary importance in the assessment of tumor resect-
ability and for the evaluation of tumor response to
chemotherapy. Contrast-enhanced computed tomog-
raphy (CE-CT) is the routinely used imaging modality
for diagnosis, staging and follow-up of TETs [15–19].
Furthermore in patients with advanced disease undergo-
ing primary or definitive chemotherapy, CE-CT is usu-
ally performed to reassess resectability or to determine
tumor response using Response Evaluation Criteria in
Solid Tumor (RECIST) [20, 21].
Functional imaging with 18F-Fluorodeoxyglucose
positron emission tomography (18F-FDG PET) with its
ability to identify more aggressive and invasive sub-
types of TETs provides useful information for the
biologically characterization of thymic masses [22–25]
and for disease stage [26–29]. Furthermore, 18F-FDG
PET-CT has been performed to monitor the efficacy
of targeted therapy in patients with advanced TETs
and a reduction of 18F-FDG uptake higher than 30%
closely correlated with objective tumor response [30].
Despite the wide use of 18F-FDG PET-CT in the
assessment of metabolic response to standard chemo-
therapy in many solid tumors [31, 32], only few studies
tested the ability of 18F-FDG PET-CT to identify
responders and non-responders to standard chemotherapy
in small series of patients with TETs [33–36]. Since meta-
bolic response usually precedes the morphovolumetric
reduction of tumor burden, the early detection of
treatment failure may indicate the need to adopt
alternative regimens [32, 37, 38]. The aim of the
present study is to test whether 18F-FDG PET-CT
performed in patients with advanced or recurrent
TETs before and after standard chemotherapy may
discriminate responders from non-responders and
whether metabolic response correlates with morpho-
volumetric RECIST criteria of tumor response.
Methods
Patients and treatment
In this retrospective monocentric study we evaluated the
medical records of twenty-seven consecutive patients, 18
male (mean age ± SD, 56 ± 12 y) and 9 female (mean age ±
SD, 57 ± 11 y), with advanced (16 patients) or recurrent (11
patients) thymic epithelial tumors who had undergone
whole-body 18F-FDG PET-CT before and after standard
chemotherapy regimens. Histopathogical diagnosis was ob-
tained in all patients and, based on WHO classification, 1
B1, 7 B2 and 7 B3 TETs along with 12 thymic carcinoma
were included in the study. All patients were staged using
the Masaoka-Koga staging system based on CE-CT findings
at presentation: 3 patients had unresectable stage III, 5 were
in stage IVA and 19 patients had stage IVB which included
a high percentage of thymic carcinomas (11 patients).
Among the 27 patients, 16 had no chemotherapy
before the basal 18F-FDG PET-CT whereas 5 patients
received prior adjuvant or neoadjuvant chemotherapy
and 6 were treated with definite chemotherapy for
advanced, unresectable TET (Table 1). Furthermore, 5
patients underwent radiation therapy after surgery or in
combination with chemotherapy. After the basal 18F-
FDG PET-CT scan, platinum-based chemotherapy was
administered to 23 patients (3-8 cycles, median 5); four
additional patients with advanced disease who were in
progression after platinum-based chemotherapy were
treated with gemcitabine-capecitabine (at least 7 cycles).
Response evaluation
Contrast-enhanced CT scan of skull, neck, chest, abdo-
men and pelvis was performed at baseline and at the
end of the planned regimen and the effects of chemo-
therapy were assessed using the RECIST version 1.1 [21].
Tumor response was defined as: complete response (CR)
when there was disappearance of all lesions; partial re-
sponse (PR) if there was ≥ 30% reduction in lesion size;
progressive disease (PD) if there was increase of more
than 20% in lesion size or appearance of a new lesion;
stable disease (SD) when no PR and no PD occurred.
For statistical purposes patients with CR and PR were
grouped in the class of responders whereas patients with
SD and PD were considered non-responders.
18F-FDG PET-CT Study
18F-FDG PET-CT scans were acquired after fasting for
8 h and 60 min after intravenous administration of
18F-FDG (350–370 MBq). The blood glucose level, mea-
sured just before tracer administration, was < 120 mg/dL
in all patients. Dual-modality imaging was performed
with a PET-CT Discovery LS scanner (GE Healthcare,
Milan, Italy) consisting of a PET scanner and a four-row
multidetector computed tomography (MDCT) system.
MDCT scan was acquired using the following
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parameters: 4 × 5 mm collimation (140 kV, 80 mAs),
0.8 s rotation time, pitch of 1.5; when indicated, a fully
diagnostic contrast-enhanced CT was performed. PET
scan was subsequently performed in 2-dimensional
mode using 4 min per bed position and six to eight bed
positions per patient, depending on patient height. Itera-
tive images reconstruction was completed with an or-
dered subsets-expectation maximization algorithm (2
iterations, 28 subsets). Attenuation corrected emission
data were obtained using filtered back projection CT re-
constructed images (Gaussian filter with 8 mm full width
half maximum) to match the PET resolution. Transaxial,
sagittal, and coronal images as well as coregistered
images were examined using Xeleris software and then
transferred in DICOM format to an OsiriX workstation
(Pixmeo, Switzerland). All areas of focal 18F-FDG uptake
visible on 2 contiguous PET slices at least and not
corresponding to physiological tracer uptake were consid-
ered to be positive [39]. The SUVmax values of all lesions
in the pre- and post-treatment scan were recorded by two
board-certified nuclear medicine physicians and discrep-
ancies between their assessments were resolved by con-
sensus through discussion. The SUVmax value of the most
metabolically active lesion in each examination was used
to define the ΔSUVmax as follows: ΔSUVmax = [(SUVmax
post – SUVmax pre)/SUVmax pre] × 100.
Statistical analysis
Statistical analysis was performed using the software
MedCalc for Windows, version 10.3.2.0, (MedCalc
Software, Mariakerke, Belgium). Data are expressed as
mean ± SD if not differently indicated. Unpaired
Student’s t test was used to compare means of normally
distributed data sets as assessed by Kolmogorov-
Smirnov test. Spearman’s rank correlation was used to
examine the association between ΔSUVmax and tumor
response. Receiver operating characteristic (ROC)
curve analysis was performed to estimate the best
value of ΔSUVmax capable of discriminating
responders from non-responders. A p value < 0.05 was
considered statistically significant.
Results
Patient characteristics are summarized in Table 1. Pre-
treatment 18F-FDG PET-CT scan showed abnormal
18F-FDG uptake in all patients detecting a total of 77
lesions, including 18 mediastinal masses, 15 lymph nodes,
23 pleura/pericardial implants, 16 visceral lesions and 5
bone lesions, with an average of 2.85 ± 2.03 lesions per
patient (range 1-8). The lesion with the highest SUVmax
value in each patient was selected as the target lesion for
the assessment of metabolic response; these 27 target
lesions showed a mean size of 52.90 mm± 21.24 mm. The
SUVmax values of those lesions ranged between 3.3
(pleural implant) and 20 (thymic carcinoma) with a mean
of 8.67 ± 4.89 (Table 2). Post-treatment 18F-FDG PET-CT
showed reduction of FDG uptake in the target lesion of 19
patients and an increase of tracer accumulation in 8
patients (Table 2). None of the patients showing reduction
of 18F-FDG in the target lesion showed the appearance of
new site of abnormal 18F-FDG uptake whereas new meta-
bolically active lesions (3 metastatic lymph nodes, 1 lung
lesion, 3 pleural implants and 1 large vessel infiltration)
were found in 5 out of 8 patients showing increased 18F-
FDG accumulation in the target lesion.
After treatment with standard chemotherapy, morpho-
volumetric tumor response was assessed by contrast-
enhanced CT. Based on RECIST criteria, an objective
tumor response was observed in 17 patients (2 CR and
15 PR) whereas in the remaining patients, 8 showed SD
and 2 had PD (Table 2).
Table 1 Clinical characteristics of patients (N = 27)
Characteristics N0 %
Age (yr)








Thymic carcinoma 12 44
Stage at presentation (Masaoka-Koga)
III 3 11
IV A 5 19





Prior therapy for advanced TETsb 6 22
Prior adjuvant/neoadjuvant therapy 5 19
No prior therapy 16 59







aWHO World Health Organization
bTETs Thymic epithelial tumors
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Normally distributed SUVmax values of pre- and post-
treatment 18F-FDG PET-CT scan in responders and non-
responders were expressed as mean ± SD and compared.
SUVmax values of pre-treatment
18F-FDG PET-CT scan
were not significantly different between responders and
non-responders (8.80 ± 5.04 vs 8.45 ± 4.88, p= 0.8645). Con-
versely SUVmax values of post-treatment
18F-FDG PET-CT
scan were significantly lower in responders as compared to
non-responders (3.94 ± 3.62 vs 8.99 ± 4.34, p = 0.0038).
The change of 18F-FDG uptake between baseline and
post-treatment scan was -46.82% ± 8.10% (SE) in re-
sponders, indicating a reduction of tracer uptake, whereas
non-responders showed an increase of 18F-FDG uptake
with a ΔSUVmax of 20.40% ± 15.75% (SE). The normally
distributed values of ΔSUVmax were significantly different
in responders and non-responders (p = 0.0003, unpaired
t-test) and were significantly correlated with morphovolu-
metric response (Spearman’s rank correlation, r = 0.64,
p = 0.001). Fig. 1 shows the distribution of ΔSUVmax
values in responders and non-responders.
Table 2 Pre- and post-treatment SUVmax and ΔSUVmax values compared to morphovolumetric tumor response assessed by RECIST
Patient Target lesion SUVmax pre
a SUVmax post
b ΔSUVmaxc (%) RECISTd
1 Mediastinal mass 10.00 7.50 −25 PR
2 Mediastinal mass 6.60 3.50 −47 PR
3 Mediastinal mass 13.00 6.20 −52 SD
4 Pleural implant 9.23 0.00 −100 CR
5 Mediastinal mass 4.10 3.00 −27 PR
6 Lung lesion 18.70 17.00 −9 SD
7 Lymph node 12.00 11.50 −4 SD
8 Pleural implant 5.80 2.10 −64 PR
9 Pleural implant 7.60 1.70 −78 PR
10 Lymph node 3.70 8.20 120 PD
11 Mediastinal mass 4.19 5.30 26 SD
12 Mediastinal mass 8.40 11.30 35 SD
13 Lung lesion 19.70 5.70 −71 PR
14 Mediastinal mass 4.20 4.60 10 PR
15 Mediastinal mass 5.00 3.00 −40 PR
16 Mediastinal mass 8.40 0.00 −100 CR
17 Pleural implant 4.00 4.80 20 PD
18 Mediastinal mass 15.60 18.5 19 PR
19 Mediastinal mass 7.70 2.20 −71 PR
20 Lung lesion 8.80 14.40 64 SD
21 Mediastinal mass 8.30 5.70 −31 PR
22 Lymph node 8.50 5.40 −36 PR
23 Pleural implant 3.30 1.90 −42 PR
24 Mediastinal mass 7.00 4.50 −36 SD
25 Mediastinal mass 5.60 1.80 −68 PR
26 Mediastinal mass 20.00 15.00 −25 PR
27 Mediastinal mass 4.80 6.70 40 SD
aSUVmax pre: pre-treatment maximum Standardized Uptake Value
bSUVmax post: post-treatment maximum Standardized Uptake Value
cΔSUVmax: percentage change in maximum Standardized Uptake Value
dRECIST Response Evaluation Criteria in Solid Tumors, CR Complete response, PR Partial response, SD Stable disease, PD, Progressive disease
Fig. 1 Distribution of ΔSUVmax values in patients allocated in the class of
responders and non-responders by RECIST criteria. Responders showed
ΔSUVmax values significantly lower than those of non-responders
(p = 0.0003, unpaired t-test) and a significant correlation was found
between ΔSUVmax values and morphovolumetric response (Spearman’s
rank correlation, r = 0.64, p = 0.001). Horizontal bar indicates mean
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ROC curve analysis showed that a ΔSUVmax value of -25%
could discriminate responders from non-responders
with a sensitivity of 88% and a specificity of 80% (Fig. 2).
Figures 3 and 4 show representative 18F-FDG PET-CT
images of baseline and post-treatment scans in a patient
with metabolic response and a patient with metabolic
progression of the disease, respectively. The responding
patient of Fig. 3 was allocated in the class of PR using
RECIST and showed a 47% reduction of tracer uptake
indicating a concordance between morphologic and
metabolic tumor response. Conversely the non-
responding patient of Fig. 4 was judged to have stable
disease by RECIST but he showed a 64% increase of 18F-
FDG uptake indicating a metabolic progression.
Discussion
The present study showed that 18F-FDG PET-CT may be
used to monitor tumor response to standard chemother-
apy in patients with advanced or recurrent TETs. The
percentage change of 18F-FDG uptake between baseline
and post-treatment scans was indeed able to discriminate
responders from non-responders and significantly corre-
lated with tumor response assessed by RECIST criteria. In
particular, a 25% reduction of 18F-FDG uptake identified
responders with a sensitivity of 88% and a specificity of
80%. Our findings are in agreement with previous studies
evaluating early metabolic response in patients with TETs
mainly treated with targeted therapy [30]. All patients in
our study received conventional chemotherapy for
advanced or recurrent disease and, being potentially can-
didate to several consecutive lines of chemotherapy,
tumor response was carefully assessed to guide subse-
quent therapeutic options.
Assessment of tumor response in patients with TETs is
usually performed using RECIST criteria in which unidi-
mensional tumor measurements are obtained from pre--
and post-treatment CT scans to evaluate changes of
tumor burden in response to therapy [20, 21]. Although
RECIST criteria are widely accepted as the standard
method to evaluate tumor response in solid tumors,
they have some limitations in TETs. In fact, TETs dif-
fer from other solid tumors in terms of growth and
dissemination patterns especially in advanced stages.
They are often large masses with indefinite borders
encasing mediastinal structures and infiltrating adjacent
tissues. Furthermore non-contiguous pleural metastases
are common in these patients and measurements of these
lenticular lesions may be difficult. In order to overcome
these limitations, International Thymic Malignancy Interest
Group proposed modified RECIST criteria for the
assessment of tumor response in TETs taking into account
the peculiar growth and dissemination patterns of the
disease [40–44].
Although standard criteria for the assessment of ob-
jective tumor response remain based on anatomical
measurements, functional imaging with 18F-FDG-PET-
CT has been used for the evaluation of metabolic
response to therapy in many solid tumors. Previous
Fig. 2 ROC curve analysis showed a sensitivity of 88% and a specificity
of 80% in discriminating responders from non-responders (arrow) using
a threshold of -25% for ΔSUVmax
Fig. 3 Representative images of baseline a and post-treatment b 18F-FDG PET-CT scan in a patient with thymic carcinoma. Fusion images
of co-registered transaxial 18F-FDG PET and contrast-enhanced CT sections are shown. In the baseline scan SUVmax was 6.60 whereas the
post-treatment study showed a SUVmax of 3.50. A 47% reduction of
18F-FDG uptake was found in this patient with partial response based
on RECIST. The same maximum threshold of SUV was applied to PET images from pre-treatment and post-treatment scans as shown by
the color scale on the left
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studies showed indeed that conventional cytotoxic
agents, by inducing tumor cell death, cause a reduction
of cell viability and glucose demand with a consequent
decrease of 18F-FDG uptake that may precede tumor
shrinkage as assessed by anatomical measurements
[32, 37, 38, 45, 46]. Due to the consistent results of a
number of studies, recommendations on the use of
18F-FDG-PET for monitoring efficacy of therapy have
been published and include EORTC (European
Organization for Research and Treatment of Cancer)
and PERCIST (PET Response Criteria in Solid
Tumors) criteria which are based on changes of tracer
uptake in response to treatment [31, 47]. Although
clinically relevant thresholds have been proposed to
classify metabolic response [48, 49] the optimal cut-
off to discriminate responders and non-responders
may vary among different malignancies depending on
their tracer uptake patterns and dynamics during
therapy. In our study, the optimal threshold that
identifies responding and non-responding TETs is in
agreement with the values proposed by both EORTC
and PERCIST recommendations.
Despite the large use of 18F-FDG in the evaluation of
metabolic response of solid tumors to therapy, it is still
not clear how many lesions should be included in the
analysis of pre and post-treatment PET scans especially
in advanced stages. Previous studies reported analysis of
both single and multiple lesions and both approaches re-
sulted to be predictive of morphovolumetric response or
outcome [48, 50]. Considering the potential association
between 18F-FDG uptake and degree of invasiveness of
TETs and the possible coexistence of different WHO
histotypes in the same tumor mass, we decide to analyse
the most 18F-FDG avid lesion in pre and post-treatment
scans in order to derive the percentage change of tracer
uptake, after ensuring that no new lesions were found or
metabolic progression occurred in all other lesions in
post-treatment 18F-FDG PET-CT. This simplified
approach may be easily employed to evaluate metabolic
response in patients with TETs in daily clinical practice
although we are aware that other volume-based meta-
bolic parameters, such as metabolic tumor volume
(MTV) and total lesion glycolysis (TLG) may better
reflect metabolic response in all lesions and be more
reliable predictive markers of survival [51].
Limitations of our monocentric study are the retro-
spective analysis of imaging findings and the relatively
limited series of patients. Therefore further studies are
needed to confirm our findings in a larger population of
patients and, since TETs are rare tumors, this may
require the involvement of several institutions.
Conclusions
Our study showed that metabolic response assessed
by 18F-FDG PET-CT may complement RECIST
criteria in the identification of responders and non-
responders thus providing an additional guide for
adaptation of therapy in patients with advanced or
recurrent thymic epithelial tumors.
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